EFZO-Fit Trial for Pulmonary Sarcoidosis
Trial Objectives
Researchers want to understand if an investigational medication called efzofitimod is safe, effective and tolerated by people with pulmonary sarcoidosis in the EFZO-Fit trial. The trial will also evaluate if efzofitimod can maintain lung function and allow people to lower their dose of steroids used as treatment for pulmonary sarcoidosis. Participants will receive a monthly IV infusion of a randomly assigned efzofitimod or a placebo (an inactive substance that looks the same and is administered the same as efzofitimod).
Who Can Participate
Adults who have a confirmed pulmonary sarcoidosis diagnosis for at least six months and have been receiving a prednisone treatment for at least three months, with a steady dose of prednisone for four weeks prior to enrolling in the study.
Age: 18-75 Gender: Any
Estimated Time Commitment
Monthly visits over 52 weeks
Payment & Reimbursement
Payment: Provided
Travel Reimbursement: Available
Trial Contact
For more information, contact:
Stephanie Leonard
303.270.2411
Trial Location
National Jewish Main Campus, Denver, CO
Trial Sponsors
aTyr Pharma, Inc.
Principal Investigators
Clara Restrepo, MD
Co-Investigators
Shu-Yi Liao, MD, MPH, ScD